Up to 4.6 years of treatment with Enspryng (satralizumab) continues to safely reduce relapse rates and prevent disability progression…
Articles by Lindsey Shapiro, PhD
For one in three people with neuromyelitis optica spectrum disorder (NMOSD), bad days — marked by high levels of…
Ad Scientiam is developing new digital biomarkers of neuromyelitis optica spectrum disorder (NMOSD) that may allow continuous and…
Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior…
The onset of neuromyelitis optica spectrum disorder (NMOSD) at an older age is linked with a greater likelihood of…
The activation of two types of immune cells — called natural killer (NK) and natural killer T-cells (NKT) — may…
Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna…
Researchers have identified a rare case of co-existing neuromyelitis optica spectrum disorder (NMOSD) and subacute combined degeneration (SCD) —…
Neutrophils, a set of immune cells, from people with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) are resistant…
In rare cases, people with neuromyelitis optica spectrum disorder (NMOSD) can experience low blood levels of neutrophils, a type…